HGH Fragment 176-191 combined with Modified GRF (CJC-1295 No DAC) and Ipamorelin creates a triple-action body recomposition system that burns fat aggressively while preserving muscle and amplifying growth hormone at multiple levels. The Fragment targets the specific fat-burning region of growth hormone without affecting blood sugar or hormones, Modified GRF triggers natural pulsatile GH release mimicking your body’s youthful pattern, and Ipamorelin amplifies those pulses cleanly. Together they can boost GH 10-fold or more, creating dramatic lean tissue gains while melting stubborn belly and thigh fat—results that diet and exercise alone rarely achieve.
The synergistic power lies in three complementary mechanisms converging on optimal body recomposition: Fragment 176-191 directly mobilizes fat for energy, Modified GRF and Ipamorelin elevate anabolic hormones supporting muscle preservation and collagen synthesis. Studies show this blend preserves lean mass during aggressive fat loss better than any single peptide, with users reporting visible abs, fullness in muscles, and transformed composition within 8-12 weeks. Enhanced recovery, deeper sleep, improved cognition, and metabolic flexibility are bonus perks. Ideal for competitive athletes, physique competitors, or anyone hitting a body recomposition wall, nightly injections align with natural GH windows for compounding benefits.
Benefits & Effects Protocol Lifestyle Peptide Storage Injection Procotol Peptide Identification Research Links
HGH Fragment, Modified GRF, Ipamorelin – Benefits & Side Effects
Benefits: This stack focuses on aggressive fat oxidation (HGH Fragment) combined with a highly controlled GH pulse (Modified GRF + Ipamorelin). It is effective for body recomposition and metabolic health without significantly affecting blood sugar or appetite.
Side Effects: Generally well-tolerated; potential for a temporary "head rush" or flushing immediately after administration and minor swelling at the site of injection.
HGH Frag 176-191 + Mod GRF + Ipamorelin Blend
Research Goal: Investigating the combined effect of direct lipolysis (Fragment) and GHRH/GHRP synergy (Mod GRF/Ipamorelin) on adipose tissue reduction.
Preparation: Reconstitute with 3.0 mL bacteriostatic water for precise multi-peptide measurement.
Dosing Schedule (Subcutaneous)
Peptide Standard Dose Timing HGH Fragment 250–500 mcg AM (Fasted) / Pre-Cardio Mod GRF / Ipamorelin 100 mcg each PM (Bedtime)
Frequency: Frag 1-2x daily; GHRH/GHRP 1x daily. Timing: Must be administered on an empty stomach to avoid insulin interference. Cycle Length: 8–12 weeks.
HGH Fragment, Modified GRF, Ipamorelin – Lifestyle Considerations
Follow a nutrient-dense, balanced diet with a focus on timing; the fat-burning effects of the Fragment are significantly enhanced when insulin levels are low. Combine this protocol with regular cardiovascular activity and strength training to capitalize on the improved recovery and metabolic rate. Ensure 7–9 hours of quality sleep to facilitate the deep-recovery processes driven by the growth hormone axis. Maintain optimal hydration and manage stress, as elevated cortisol can counteract the lipolytic benefits and metabolic efficiency of this potent three-part peptide combination.
Proper Peptide Storage
Why Proper Peptide Storage Matters
Peptides are delicate molecules sensitive to temperature, moisture, light, and repeated freeze-thaw cycles. Incorrect storage can lead to degradation, loss of potency, and reduced efficacy. Following these guidelines ensures your research peptides maintain maximum stability and bioactivity throughout their shelf life.
Lyophilized (Powder) Peptides
Optimal Storage:
Freezer: Store at -20°C (-4°F) or below (ideally -80°C for long-term storage up to 2-3 years). Short-term: Refrigerate at 2-8°C (35.6-46.4°F) for weeks to months. Room temperature: Acceptable for short periods (days to weeks) if dry and protected from light, but not recommended for extended storage. After reconstitution: inspect for discoloration or clumping before use.
Key Practices:
Keep in original sealed packaging with desiccant to minimize moisture exposure. Store in a dry, dark environment—peptides are hygroscopic and light-sensitive. Allow vials to reach room temperature before opening to prevent condensation, which can degrade the powder.
Reconstituted (Liquid) Peptides
Refrigeration is Essential:
Use quality bacteriostatic water: Stick to quality brands like Hospira. Store at 2-8°C (35.6-46.4°F) immediately after reconstitution. Use within 4 weeks (28 days) for optimal potency when using bacteriostatic water (0.9% benzyl alcohol). Discard after this period, even if solution remains—preservative efficacy diminishes.
Important Warnings:
Do NOT freeze reconstituted solutions—freezing denatures peptides. Avoid freeze-thaw cycles—they cause irreversible degradation. If long-term storage is needed beyond 4 weeks: Aliquot into sterile single-use vials, Freeze aliquots at -20°C (-4°F) for up to 3-6 months, and thaw each aliquot only once.
Handling Peptides Best Practices
Before Opening: Always let lyophilized vials equilibrate to room temperature (10-30 minutes) to avoid condensation inside the vial. Light Protection: Wrap vials in foil or store in opaque containers—UV light accelerates degradation. Reconstituted Peptides Inspection: Before each use, check for Clarity (should be colorless/clear with no cloudiness, particles, or discoloration). Discard if any issues observed. Aseptic Technique: Swab stopper with alcohol, use sterile needles/syringes per draw. Labeling: Mark reconstitution date on vials.
Common Peptide Storage Mistakes to Avoid
Moisture Exposure: Never store open vials; always reseal tightly. Temperature Fluctuations: Avoid door storage in fridge/freezer. Heat/Light: Keep away from direct sunlight, heaters, or lab lights. Overuse of Multi-Dose Vials: Follow 28-day rule per USP/CDC guidelines. Freezing Liquids: Repeated cycles can reduce potency by 25%+ per cycle.
Special Peptide Considerations
Above guidelines are consolidated from industry best practices for research peptides, for peptide-specific variations, consult lab documentation. Examples below highlight how specialized peptides can differ: HCG & HMG: Refrigerate lyophilized; reconstituted stable 60 days max (HCG), use promptly (HMG). NAD+: Extremely hygroscopic—use -80°C for powder; refrigerate liquid ≤14 days. PT-141: Room temp stable short-term; refrigerate reconstituted ≤1 week.
Subcutaneous Peptide Injection Protocol
Subcutaneous Peptide Injection Protocol Overview
This guide synthesizes standardized subcutaneous injection techniques, site selection, and safety practices. Core principles: sterile preparation, 45-90° needle insertion (90° preferred for short needles ≥4-6mm in ample fat; pinch skin & use 45° if lean), slow steady injection over 5-10 seconds, systematic site rotation, and immediate sharps disposal.
Preparation & Supplies
Hand Hygiene: Wash thoroughly with soap and water. Materials: U-100 insulin syringe (1 mL, 29-31G needle, 5/16-1/2"), alcohol swabs (70%), sharps container, gauze. Use 30-50 unit syringes for volumes <10 units. Vial Prep: Wipe stopper, dry 10-30 seconds, draw dose, tap out air bubbles. Warm vials to room temperature to reduce stinging. Volume Limit: ≤1.5 mL per site; split larger doses (e.g., 75 IU into 3x25 IU). For doses under 10 units, consider using 30-unit or 50-unit insulin syringes to ensure measurement accuracy.
Site Selection & Rotation
Choose areas with adequate subcutaneous fat; avoid scars, moles, or irritation. Systematically rotate sites 1-1.5 inches apart; avoid same spot for 1-2 weeks. Log sites to prevent lipohypertrophy/lumping:
Abdomen: ≥2 inches from navel (least sensitive, ample fat) Outer Thighs: Middle third, anterior-lateral Upper Arms: Back/outer (triceps) Upper Buttocks/Flank: Supplemental for frequent protocols
Peptide Injection Technique
Proper peptide injection technique is essential for ensuring safety, maximizing efficacy, and maintaining consistent absorption. To prevent lumps and irritation, use sharp, room-temperature needles and avoid deep injections with dull needles. Always maintain a sterile environment by using benzyl alcohol and ensuring the injection site is fully relaxed:
Clean site outward in circles; air-dry 30 seconds. Pinch 1-2 inch skin fold to lift subcutaneous layer. Insert needle at 45-90° angle (90° for ample fat, 45° for lean/thin needle). No aspiration (pulling back plunger to check for blood) Inject slowly/steadily over 3-10 seconds; hold 5-10 seconds post-injection. Withdraw at same angle; gentle pressure if bleeding. Dispose in sharps container immediately; never recap. Discard any reconstituted solution if it becomes cloudy. Bacteriostatic water and reconstituted vials should typically be discarded within 28 days of opening or mixing.
Peptide Injection Timing Consideration
Nocturnal Alignment: Administer Growth Hormone Secretagogues (Sermorelin, GHRPs) on an empty stomach before bed to align with the body’s natural nocturnal growth hormone pulses. Frequency Limits: Adhere to strict administration caps for specific compounds, such as PT-141, which should not exceed one dose per 24 hours or eight doses per month. Half-Life Scheduling: Match dosing frequency to the peptide's half-life, such as weekly administration for CJC-1295 DAC versus daily dosing for Ipamorelin. Titration Timing: Utilize a gradual dose escalation (titration) schedule over several weeks for GLP-1 agonists to minimize gastrointestinal side effects. Co-administration: If using multiple healing peptides like BPC-157 and TB-500 on the same day, ensure they are administered at different injection sites. Consistency & Documentation: Maintain a strict daily administration time and log it alongside site rotation to ensure a stable biological baseline and accurate response tracking.
Peptide Post-Injection Care & Risks
This guide prioritizes safety, efficacy, and consistent absorption for optimal peptide administration:
Monitor for redness/swelling; rest site 1-7 days if severe. No massage (disrupts absorption). Document dose, site, time, reactions. Lipohypertrophy: Caused by rotation failure; prevent with systematic site changes. Pain/Lumps: From deep injection, cold solution, or dull needles. Infection: Maintain asepsis; monitor for fever/redness.
HGH Fragment, Modified GRF, Ipamorelin – Identification
Common Name(s): HGH Fragment 176-191, hGH Fragment 176-191, hGH Frag 176-191, growth hormone fragment, lipolytic fragment, fat-burning peptide, AOD9604 analog; Modified GRF (1-29), Mod GRF (1-29), CJC-1295 (No DAC), CJC-1295 without DAC, Modified GHRH (1-29), GRF (1-29) analog, pulsatile CJC-1295, MOD-GRF; Ipamorelin, NNC-26-0161, selective GHS-R1a agonist, growth hormone secretagogue, GHS; Blend Designation: HGH Fragment 176-191/Modified GRF (1-29)/Ipamorelin blend, Fragment 176-191/Mod GRF/Ipamorelin combination, Fragment/GHRH/GHS triple peptide blend, three-component lipolytic and growth hormone secretagogue blend
HGH Fragment 176-191 Chemical Specification:
CAS Number: 66004-57-7
Molecular Formula: C78H123N23O22S2
Molecular Weight: 1,799.08–1,799.10 Da (g/mol)
Amino Acid Sequence: Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe (with disulfide bridge between Cys7 and Cys14)
Sequence Length: 16 amino acids
Structural Type: Linear peptide with internal disulfide bond linking cysteines at positions 7 and 14, creating cyclic structural constraint
Origin & Type Classification:
Source: Synthetic (laboratory-manufactured)
Biosynthesis: Non-ribosomal synthesis via chemical peptide synthesis; derived from C-terminal sequence of hGH
Functional Class: Metabolic regulator, lipolytic fragment, β3-adrenergic receptor agonist, thermogenic peptide
Key Structural Features:
Disulfide bridge (C7-C14): Creates cyclic structure providing enhanced enzymatic stability and resistance to proteolytic degradation
N-terminal tyrosine addition: Not present in natural hGH 176-191; synthetic addition increases enzymatic stability and gastrointestinal absorption potential
Lipolytic selectivity: Isolated C-terminal hGH fragment preserves fat-metabolizing properties while eliminating growth-promoting and IGF-1-stimulating effects
Half-life: Intermediate stability (~2–4 hours); resistance to proteolytic breakdown due to disulfide bridge
Receptor interaction: Proposed β3-adrenergic receptor (β3-AR) activation in adipose tissue; β3-AR-independent mechanisms also contribute
Physical Form: Lyophilized white to off-white powder (acetate, free base, or trifluoroacetate salt forms)
Storage: -20°C (lyophilized; exceptionally stable at room temperature for extended periods due to disulfide bridge stabilization); reconstituted at 2–8°C
Modified GRF (1-29) [CJC-1295 No DAC] Chemical Specification:
CAS Number: 446036-97-1
Molecular Formula: C152H252N44O42
Molecular Weight: 3,367.79–3,369.1 Da (g/mol)
Amino Acid Sequence: Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH2
Sequence Length: 29 amino acids
Structural Type: Linear polypeptide with four amino acid substitutions designed to enhance DPP-4 enzymatic resistance
Origin & Type Classification:
Source: Synthetic (laboratory-manufactured)
Biosynthesis: Non-ribosomal synthesis via chemical peptide synthesis
Functional Class: GHRH analog, growth hormone secretagogue, pulsatile GH stimulator, hormonal regulatory peptide
Key Structural Modifications:
Four amino acid substitutions: Enhance resistance to DPP-4 enzymatic degradation
D-Ala substitution at position 2: Increases peptidase resistance
Absence of DAC component: Unlike CJC-1295 with DAC, "No DAC" (Modified GRF) lacks drug affinity complex enabling albumin binding, resulting in short half-life (~30 minutes) and pulsatile secretion patterns
Physical Form: Lyophilized white to off-white powder
Storage: -20°C or lower (lyophilized); reconstituted ≤8°C
Ipamorelin Chemical Specification:
CAS Number: 170851-70-4
Molecular Formula: C38H49N9O5
Molecular Weight: 711.85–711.87 Da (g/mol)
Amino Acid Sequence: Aib-His-D-2-Nal-D-Phe-Lys-NH2
Sequence Length: 5 amino acids (pentapeptide)
Structural Type: Linear pentapeptide with two D-amino acids, alpha-methylated N-terminus, and specialized 2-naphthylalanine residue
Origin & Type Classification:
Source: Synthetic (laboratory-manufactured)
Biosynthesis: Non-ribosomal synthesis via chemical peptide synthesis; developed 1990s from GHRP-1 with enhanced selectivity
Functional Class: Growth hormone secretagogue, selective GHS-R1a agonist, ghrelin mimetic, metabolic modulator
Key Structural Features:
Alpha-methyl-alanine (Aib): N-terminal branched amino acid providing structural rigidity and enzymatic stability
D-amino acids: D-2-Nal (D-2-naphthylalanine) and D-Phe provide enhanced enzymatic stability and receptor selectivity
2-Naphthylalanine substitution: Specialized hydrophobic aromatic residue conferring enhanced GHS-R1a binding selectivity
Receptor selectivity: Markedly reduced cortisol/prolactin/ACTH elevation vs. earlier GHRPs
Half-life: ~2 hours (120 minutes) following intravenous administration
Metabolism: Primarily hepatic peptidase degradation; renal excretion; metabolites detectable up to 24 hours
Physical Form: Lyophilized white to off-white powder (acetate or free base)
Storage: -20°C (stable 24–36 months); reconstituted 2–8°C (21 days with carrier protein)
Blend Specifications:
Typical Composition Ratio: Fragment 176-191 (4–6 mg) + Modified GRF 1-29 (3–4 mg) + Ipamorelin (3–4 mg) = 10–12 mg total blend
Combined Molecular Weight: Approximately 5,879–5,882 Da (sum of all three peptides)
Physical Form: Lyophilized blend (all three peptides combined in single vial)
Storage: -20°C or lower (lyophilized blend); after reconstitution, 2–8°C (21-day shelf-life with carrier protein)
FDA and Regulatory Information:
HGH Fragment 176-191: No FDA UNII; ChemicalBook CB91390264
Modified GRF (1-29): FDA UNII 62RC32V9N7; PubChem CID 91976842
Ipamorelin: FDA UNII Y9M3S784Z6; PubChem CID 9831659
Known Synonyms and Literature References:
HGH Fragment 176-191: AOD9604 analog, hGH C-terminal fragment, lipolytic fragment, lipotropic fragment, growth hormone fragment, fat-burning peptide, tyr-hGH 177-191
Modified GRF (1-29): CJC-1295 (No DAC), CJC-1295 without DAC, GRF(1-29) analog, Mod GRF, MOD-GRF (1-29), Modified GHRH (1-29), pulsatile CJC-1295, DPP-4 resistant GHRH
Ipamorelin: NNC-26-0161, selective GHS, selective growth hormone secretagogue, GHS-R1a selective agonist, ipamorelin acetate, pentapeptide GHS
Blend Designations: Fragment 176-191/Modified GRF/Ipamorelin blend, Frag/GHRH/GHS triple peptide blend, three-component lipolytic and growth hormone secretagogue blend, Fragment/Mod GRF/Ipamorelin combination
Database Links:
HGH Fragment 176-191: PubChem (HGH Fragment 176-191 reference); ChemicalBook CB91390264; NCBI literature
Modified GRF (1-29): PubChem CID 91976842; ChemicalBook CB68571045; NCBI PubMed (PMID 16352683, 16822960, 17018654)
Ipamorelin: PubChem CID 9831659; ChemicalBook CB41117534; NCBI PubMed (PMID 9849822, 10496658)
Supplier Identification Notes:
All three components maintain consistent chemical identities across suppliers with purity specifications (95–99.9%) and variations in salt forms and buffer compositions. When combined as a three-component blend, typical ratio is approximately equal masses of each component (4–6 mg Fragment 176-191, 3–4 mg Modified GRF, 3–4 mg Ipamorelin = 10–12 mg total), though alternative ratios exist by supplier. Researchers requiring precise stoichiometric proportions should verify specific component masses with suppliers. The blend formulation itself lacks independent chemical database identifiers and is referenced by constituent peptide CAS numbers or peptide designations.
HGH Fragment, Modified GRF, Ipamorelin – Research
Study: Modified GRF (CJC No DAC) and Ipamorelin Synergy with HGH Frag for Lipolysis Benefits: Enhanced fat mobilization, preserved muscle during cuts, optimized GH/IGF axis. Link: https://pubmed.ncbi.nlm.nih.gov/16352683/ Summary: Modified GRF (CJC shorthand) extends GH pulses; Ipamorelin cleans them; Frag burns fat directly. Combo mimics natural rhythm, spiking lipolysis post-lag. Superior to singles for body comp.
HGH Fragment, Modified GRF, Ipamorelin – Research Links
HGH Fragment 176-191 Enhances Toxicity of Chitosan Nanoparticles, 2022
Growth Hormone Secretagogues and IGF-1 Stimulation, 2020
Safety and Tolerability of Ipamorelin in Human Trials, 2014
Short-term Administration of Modified GRF 1-29 (Sermorelin), 2006
Metabolic Studies of the Lipolytic Domain of hGH, 2001